insights_auto
Bakit tumaas ang 6160 4.36%?
Tingnan ang Higit pang Detalyechevron_right
6160:HKG
BeOne Medicines AG
HK$225.00
arrow_upward
+4.36%(+9.40) 1D
Okt 16, 4:08:14 PM GMT+8 · HKD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa 6160...
Buksan
HK$224.80
Mataas
HK$230.20
Mababa
HK$221.80
Mkt. cap
355.76B
Avg. na dami
2.93M
Dami
4.41M
P/E ratio
65.67
Mataas nang 52-wk
HK$235.60
Mababa nang 52-wk
HK$153.00
EPS
HK$3.43
Mga natitirang share
1.43B
Bilang ng mga empleyado
12K
Buksan
HK$224.80
Mataas
HK$230.20
Mababa
HK$221.80
Mkt. cap
355.76B
Avg. na dami
2.93M
Dami
4.41M
P/E ratio
65.67
Mataas nang 52-wk
HK$235.60
Mababa nang 52-wk
HK$153.00
EPS
HK$3.43
Mga natitirang share
1.43B
Bilang ng mga empleyado
12K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
MarketBeat
·
3 araw ang nakalipas
TB Alternative Assets Ltd. Makes New $5.42 Million Investment in BeOne Medicines Ltd. - Sponsored ADR $ONC
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Tungkol sa BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Mga Empleyado12K
ItinatagOkt 28, 2010
Headquarters-
Sektor-
Websitebeonemedicines.com